-
1
-
-
85025476425
-
-
Influenza Web Page., (accessed on 5 September 2016)
-
World Health Organization. Influenza Web Page. Available online: http://www.who.int/mediacentre/ factsheets/fs211/en/ (accessed on 5 September 2016).
-
-
-
-
2
-
-
85025475688
-
Weekly epidemiological record Relevé épidémiologique hebdomadaire
-
World Health Organization (WHO). Weekly epidemiological record Relevé épidémiologique hebdomadaire. ANNÉE 2014, 89, 245–256.
-
(2014)
ANNÉE
, vol.89
, pp. 245-256
-
-
-
4
-
-
59049093098
-
The influenza virus enigma
-
Salomon, R.; Webster, R.G. The influenza virus enigma. Cell 2009, 3, 402–410. [CrossRef] [PubMed]
-
(2009)
Cell
, vol.3
, pp. 402-410
-
-
Salomon, R.1
Webster, R.G.2
-
5
-
-
0037135669
-
Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control
-
Hilleman, M.R. Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control. Vaccine 2002, 20, 3068–3087. [CrossRef]
-
(2002)
Vaccine
, vol.20
, pp. 3068-3087
-
-
Hilleman, M.R.1
-
6
-
-
85025430557
-
-
(accessed on 22 May 2017)
-
European Centre for Disease Prevention and Control. Available online: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx (accessed on 22 May 2017).
-
-
-
-
7
-
-
0032078697
-
Development of a mammalian cell (Vero) derived candidate influenza virus vaccine
-
Kistner, O.; Barrett, P.N.; Mundt, W.; Reiter, M.; Schober-Bendixen, S.; Dorner, F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16, 960–968. [CrossRef]
-
(1998)
Vaccine
, vol.16
, pp. 960-968
-
-
Kistner, O.1
Barrett, P.N.2
Mundt, W.3
Reiter, M.4
Schober-Bendixen, S.5
Dorner, F.6
-
8
-
-
77953630380
-
Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses
-
Pandey, A.; Singh, N.; Sambhara, S.; Mittal, S.K. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccin 2010, 6, 178–188. [CrossRef] [PubMed]
-
(2010)
Hum. Vaccin
, vol.6
, pp. 178-188
-
-
Pandey, A.1
Singh, N.2
Sambhara, S.3
Mittal, S.K.4
-
9
-
-
85025441001
-
-
(accessed on 24 June 2017)
-
Centers for Disease Control and Prevention. How Influenza (Flu) Vaccines Are Made. Available online: https://www.cdc.gov/flu/protect/vaccine/how-fluvaccine-made.htm (accessed on 24 June 2017).
-
How Influenza (Flu) Vaccines are Made
-
-
-
10
-
-
85025443579
-
-
(accessed on 24 June 2017)
-
Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Total Doses Distributed. Available online: https://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm (accessed on 24 June 2017).
-
Seasonal Influenza Vaccine Total Doses Distributed
-
-
-
11
-
-
84994008683
-
History and evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines
-
Barberis, I.; Myles, P.; Ault, S.K.; Bragazzi, N.L.; Martini, M. History and evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines. J. Prev. Med. Hyg. 2016, 57, 115–120.
-
(2016)
J. Prev. Med. Hyg
, vol.57
, pp. 115-120
-
-
Barberis, I.1
Myles, P.2
Ault, S.K.3
Bragazzi, N.L.4
Martini, M.5
-
12
-
-
0029162495
-
Cell culture as a substrate for the production of influenza vaccines: Memorandum from a WHO meeting
-
World Health Organization (WHO). Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. 1995, 73, 431–435.
-
(1995)
Bull. World Health Organ
, vol.73
, pp. 431-435
-
-
-
13
-
-
65649125562
-
Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines
-
Barrett, P.N.; Mundt, W.; Kistner, O.; Howard, M.K. Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 2009, 8, 607–618. [CrossRef] [PubMed]
-
(2009)
Expert Rev. Vaccines
, vol.8
, pp. 607-618
-
-
Barrett, P.N.1
Mundt, W.2
Kistner, O.3
Howard, M.K.4
-
14
-
-
84865414271
-
Preflucel®: A Vero-cell culture-derived trivalent influenza vaccine
-
Chan, C.Y.; Tambyah, P.A. Preflucel®: A Vero-cell culture-derived trivalent influenza vaccine. Expert Rev. Vaccines 2012, 11, 759–773. [CrossRef] [PubMed]
-
(2012)
Expert Rev. Vaccines
, vol.11
, pp. 759-773
-
-
Chan, C.Y.1
Tambyah, P.A.2
-
15
-
-
70349301585
-
Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture
-
Szymczakiewicz-Multanowska, A.; Groth, N.; Bugarini, R.; Lattanzi, M.; Casula, D.; Hilbert, A.; Tsai, T.; Podda, A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 2009, 200, 841–848. [CrossRef] [PubMed]
-
(2009)
J. Infect. Dis.
, vol.200
, pp. 841-848
-
-
Szymczakiewicz-Multanowska, A.1
Groth, N.2
Bugarini, R.3
Lattanzi, M.4
Casula, D.5
Hilbert, A.6
Tsai, T.7
Podda, A.8
-
16
-
-
77956231719
-
Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine
-
Onions, D.; Egan, W.; Jarrett, R.; Novicki, D.; Gregersen, J.P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010, 38, 544–551. [CrossRef] [PubMed]
-
(2010)
Biologicals
, vol.38
, pp. 544-551
-
-
Onions, D.1
Egan, W.2
Jarrett, R.3
Novicki, D.4
Gregersen, J.P.5
-
17
-
-
0028860812
-
Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: Implications for vaccine manufacture
-
Robertson, J.S.; Cook, P.; Attwell, A.M.; Williams, S.P. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: Implications for vaccine manufacture. Vaccine 1995, 13, 1583–1588. [CrossRef]
-
(1995)
Vaccine
, vol.13
, pp. 1583-1588
-
-
Robertson, J.S.1
Cook, P.2
Attwell, A.M.3
Williams, S.P.4
-
19
-
-
84929297885
-
Flucelvax (Optaflu) for seasonal influenza
-
Manini, I.; Domnich, A.; Amicizia, D.; Rossi, S.; Pozzi, T.; Gasparini, R.; Panatto, D.; Montomoli, E. Flucelvax (Optaflu) for seasonal influenza. Expert Rev. Vaccines 2015, 14, 789–804. [CrossRef] [PubMed]
-
(2015)
Expert Rev. Vaccines
, vol.14
, pp. 789-804
-
-
Manini, I.1
Domnich, A.2
Amicizia, D.3
Rossi, S.4
Pozzi, T.5
Gasparini, R.6
Panatto, D.7
Montomoli, E.8
-
20
-
-
67449102487
-
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines)
-
Doroshenko, A.; Halperin, S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 2009, 8, 679–688. [CrossRef] [PubMed]
-
(2009)
Expert Rev. Vaccines
, vol.8
, pp. 679-688
-
-
Doroshenko, A.1
Halperin, S.A.2
-
21
-
-
85025455952
-
-
(accessed on 24 May 2017)
-
U.S. Food & Drug Administration. Vaccines, Blood & Biologics. Available online: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328684.htm (accessed on 24 May 2017).
-
-
-
-
22
-
-
72449127030
-
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
-
Clark, T.W.; Pareek, M.; Hoschler, K.; Dillon, H.; Nicholson, K.G.; Groth, N.; Stephenson, I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 2009, 361, 2424–2435. [CrossRef] [PubMed]
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 2424-2435
-
-
Clark, T.W.1
Pareek, M.2
Hoschler, K.3
Dillon, H.4
Nicholson, K.G.5
Groth, N.6
Stephenson, I.7
-
23
-
-
84866497171
-
Prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic
-
Reynales, H.; Astudillo, P.; de Vallière, S.; Hatz, C.; Schlagenhauf, P.; Rath, B.; Velentgas, P.; Fariña, A.; Sales-Carmona, V.; Groth, N. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. Vaccine 2012, 30, 6436–6443. [CrossRef] [PubMed]
-
(2012)
Vaccine
, vol.30
, pp. 6436-6443
-
-
Reynales, H.1
Astudillo, P.2
De Vallière, S.3
Hatz, C.4
Schlagenhauf, P.5
Rath, B.6
Velentgas, P.7
Fariña, A.8
Sales-Carmona, V.9
Groth, N.A.10
-
24
-
-
85025453152
-
-
(accessed on 25 May 2017)
-
Celvapan—-H1N1 Pandemic Influenza Vaccine. Available online: www.drugdevelopment-echnology.com/projects/celvapan/ (accessed on 25 May 2017).
-
-
-
-
25
-
-
84861981761
-
Clinical development of a Vero cell culture-derived seasonal influenza vaccine
-
Ehrlich, H.J.; Berezuk, G.; Fritsch, S.; Aichinger, G.; Singer, J.; Portsmouth, D.; Hart, M.K.; El-Amin, W.; Kistner, O.; Barrett, P.N. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012, 30, 4377–4386. [CrossRef] [PubMed]
-
(2012)
Vaccine
, vol.30
, pp. 4377-4386
-
-
Ehrlich, H.J.1
Berezuk, G.2
Fritsch, S.3
Aichinger, G.4
Singer, J.5
Portsmouth, D.6
Hart, M.K.7
El-Amin, W.8
Kistner, O.9
Barrett, P.N.10
-
26
-
-
79952101274
-
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: A multicentre, double-blind, randomised, placebo-controlled trial
-
Barrett, P.N.; Berezuk, G.; Fritsch, S.; Aichinger, G.; Hart, M.K.; El-Amin, W.; Kistner, O.; Ehrlich, H.J. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377, 751–759. [CrossRef]
-
(2011)
Lancet
, vol.377
, pp. 751-759
-
-
Barrett, P.N.1
Berezuk, G.2
Fritsch, S.3
Aichinger, G.4
Hart, M.K.5
El-Amin, W.6
Kistner, O.7
Ehrlich, H.J.8
-
28
-
-
61349200100
-
A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine
-
Cox, R.J.; Madhun, A.S.; Hauge, S.; Sjursen, H.; Major, D.; Kuhne, M.; Höschler, K.; Saville, M.; Vogel, F.R.; Barclay, W.; et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27, 1889–1897. [CrossRef] [PubMed]
-
(2009)
Vaccine
, vol.27
, pp. 1889-1897
-
-
Cox, R.J.1
Madhun, A.S.2
Hauge, S.3
Sjursen, H.4
Major, D.5
Kuhne, M.6
Höschler, K.7
Saville, M.8
Vogel, F.R.9
Barclay, W.10
-
29
-
-
70649103793
-
Development of a simple and high-yielding fed-batch process for the production of influenza vaccines
-
Meghrous, J.; Mahmoud, W.; Jacob, D.; Chubet, R.; Cox, M.; Kamen, A.A. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines. Vaccine 2009, 28, 309–316. [CrossRef] [PubMed]
-
(2009)
Vaccine
, vol.28
, pp. 309-316
-
-
Meghrous, J.1
Mahmoud, W.2
Jacob, D.3
Chubet, R.4
Cox, M.5
Kamen, A.A.6
-
30
-
-
84922335468
-
Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process
-
Buckland, B.; Boulanger, R.; Fino, M.; Srivastava, I.; Holtz, K.; Khramtsov, N.; McPherson, C.; Meghrous, J.; Kubera, P.; Cox, M.M. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine 2014, 32, 5496–5502. [CrossRef] [PubMed]
-
(2014)
Vaccine
, vol.32
, pp. 5496-5502
-
-
Buckland, B.1
Boulanger, R.2
Fino, M.3
Srivastava, I.4
Holtz, K.5
Khramtsov, N.6
McPherson, C.7
Meghrous, J.8
Kubera, P.9
Cox, M.M.10
-
31
-
-
77951671015
-
Vaccines Europe 2009
-
Mukhopadhyay, T.K. Vaccines Europe 2009. Expert Rev. Vaccines 2010, 9, 125–128. [CrossRef] [PubMed]
-
(2010)
Expert Rev. Vaccines
, vol.9
, pp. 125-128
-
-
Mukhopadhyay, T.K.1
-
32
-
-
84863393057
-
Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza
-
Shoji, Y.; Chichester, J.A.; Jones, M.; Manceva, S.D.; Damon, E.; Mett, V.; Musiychuk, K.; Bi, H.; Farrance, C.; Shamloul, M.; et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum. Vaccines 2011, 7, 41–50. [CrossRef]
-
(2011)
Hum. Vaccines
, vol.7
, pp. 41-50
-
-
Shoji, Y.1
Chichester, J.A.2
Jones, M.3
Manceva, S.D.4
Damon, E.5
Mett, V.6
Musiychuk, K.7
Bi, H.8
Farrance, C.9
Shamloul, M.10
-
33
-
-
84897110525
-
Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults
-
Cummings, J.F.; Guerrero, M.L.; Moon, J.E.; Waterman, P.; Nielsen, R.K.; Jefferson, S.; Gross, F.L.; Hancock, K.; Katz, J.M.; Yusibov, V. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults. Vaccine 2014, 32, 2251–2259. [CrossRef] [PubMed]
-
(2014)
Vaccine
, vol.32
, pp. 2251-2259
-
-
Cummings, J.F.1
Guerrero, M.L.2
Moon, J.E.3
Waterman, P.4
Nielsen, R.K.5
Jefferson, S.6
Gross, F.L.7
Hancock, K.8
Katz, J.M.9
Yusibov, V.10
-
34
-
-
66749137687
-
Vaccination strategies and vaccine formulation for epidemic and pandemic influenza control
-
Kreijtz, J.H.; Osterhaus, A.D.; Rimmelzwaan, G.F. Vaccination strategies and vaccine formulation for epidemic and pandemic influenza control. Hum. Vaccines 2009, 5, 126–135. [CrossRef]
-
(2009)
Hum. Vaccines
, vol.5
, pp. 126-135
-
-
Kreijtz, J.H.1
Osterhaus, A.D.2
Rimmelzwaan, G.F.3
-
35
-
-
84921462712
-
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A/H5N1 vaccine: A randomised, double-blind phase 1/2a clinical trial
-
Kreijtz, J.H.; Goeijenbier, M.; Moesker, F.M.; van den Dries, L.; Goeijenbier, S.; De Gruyter, H.L.; Lehmann, M.H.; Mutsert, G.D.; van de Vijver, D.A.; Volz, A.; et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A/H5N1 vaccine: A randomised, double-blind phase 1/2a clinical trial. Lancet Infect. Dis. 2014, 14, 1196–1207. [CrossRef]
-
(2014)
Lancet Infect. Dis.
, vol.14
, pp. 1196-1207
-
-
Kreijtz, J.H.1
Goeijenbier, M.2
Moesker, F.M.3
Van Den Dries, L.4
Goeijenbier, S.5
De Gruyter, H.L.6
Lehmann, M.H.7
Mutsert, G.D.8
Van De Vijver, D.A.9
Volz, A.10
-
36
-
-
0027411456
-
Heterologous protection against influenza by injection of DNA encoding viral protein
-
Ulmer, J.B.; Donnelly, J.J.; Parker, S.E.; Rhodes, G.H.; Felgner, P.L.; Dwarki, V.J.; Gromkowski, S.H.; Deck, R.R.; DeWitt, C.M.; Friedman, A.; et al. Heterologous protection against influenza by injection of DNA encoding viral protein. Science 1993, 259, 1745–1749. [CrossRef] [PubMed]
-
(1993)
Science
, vol.259
, pp. 1745-1749
-
-
Ulmer, J.B.1
Donnelly, J.J.2
Parker, S.E.3
Rhodes, G.H.4
Felgner, P.L.5
Dwarki, V.J.6
Gromkowski, S.H.7
Deck, R.R.8
Dewitt, C.M.9
Friedman, A.10
-
37
-
-
84928825136
-
Emerging influenza viruses and the prospect of a universal influenza virus vaccine
-
Krammer, F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol. J. 2015, 10, 690–701. [CrossRef] [PubMed]
-
(2015)
Biotechnol. J.
, vol.10
, pp. 690-701
-
-
Krammer, F.1
-
38
-
-
84959349464
-
Novel universal influenza virus vaccine approaches
-
Krammer, F. Novel universal influenza virus vaccine approaches. Curr. Opin. Virol. 2016, 17, 95–103. [CrossRef] [PubMed]
-
(2016)
Curr. Opin. Virol.
, vol.17
, pp. 95-103
-
-
Krammer, F.1
-
39
-
-
67349117322
-
Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK
-
Minor, P.D.; Engelhardt, O.G.; Wood, J.M.; Robertson, J.S.; Blayer, S.; Colegate, T.; Fabry, L.; Heldens, J.G.; Kino, Y.; Kistner, O.; et al. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009, 27, 2907–2913. [CrossRef] [PubMed]
-
(2009)
Vaccine
, vol.27
, pp. 2907-2913
-
-
Minor, P.D.1
Engelhardt, O.G.2
Wood, J.M.3
Robertson, J.S.4
Blayer, S.5
Colegate, T.6
Fabry, L.7
Heldens, J.G.8
Kino, Y.9
Kistner, O.10
-
40
-
-
44749090301
-
A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine
-
Gregersen, J.P. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 2008, 26, 3332–3340. [CrossRef] [PubMed]
-
(2008)
Vaccine
, vol.26
, pp. 3332-3340
-
-
Gregersen, J.P.1
-
41
-
-
0037095578
-
Influenza DNA vaccines
-
Ulmer, J.B. Influenza DNA vaccines. Vaccine 2002, 20, 74–76. [CrossRef]
-
(2002)
Vaccine
, vol.20
, pp. 74-76
-
-
Ulmer, J.B.1
-
42
-
-
84921676353
-
Rapid production of synthetic influenza vaccines
-
Dormitzer, P.R. Rapid production of synthetic influenza vaccines. Curr. Top. Microbiol. Immunol. 2015, 386, 237–273. [CrossRef] [PubMed]
-
(2015)
Curr. Top. Microbiol. Immunol.
, vol.386
, pp. 237-273
-
-
Dormitzer, P.R.1
-
43
-
-
18844389483
-
Influenza vaccines: Recent advances in production technologies
-
Bardiya, N.; Bae, J.H. Influenza vaccines: Recent advances in production technologies. Appl. Microbiol. Biotechnol. 2005, 67, 299–305. [CrossRef] [PubMed]
-
(2005)
Appl. Microbiol. Biotechnol.
, vol.67
, pp. 299-305
-
-
Bardiya, N.1
Bae, J.H.2
|